Nirsevimab Coverage, Children 0 to 7 months, United States

• 2025

  Log in to bookmark this resource.

  Log in

---

Access Resources

• SummaryEN
• Ask aRCie About This Resource

About

The report describes how nirsevimab coverage for infants 0 to 7 months is tracked in the U.S. using data from Immunization Information Systems (IIS). It explains that the data is collected monthly and includes children who received at least one dose since April 2024. The report notes differences between IIS and National Immunization Survey estimates, highlighting potential inaccuracies due to varying data quality across jurisdictions. Some areas may not be included if they don't submit their information on time, and different regions might have unique vaccination schedules based on local virus patterns.

---

Tags

Focus Area: Infectious Disease

Audiences: Nurses; Physicians

Emergency Management Stages: Response; Preparedness (Prevention / Protection)

Bundles: Nirsevimab Library

Keywords: Infant, Newborn; United States; Immunization Programs; Vaccination Coverage

Institutions: Centers for Disease Control and Prevention (CDC)

---

More like this

Clinical Considerations for Pregnant Women with Possible Zika Virus Infection 2024 · Centers for Disease Control and Prevention (CDC) Clinical Treatment of Monkeypox 2025 · Centers for Disease Control and Prevention (CDC) Diagnostic Testing for Monkeypox 2025 · Centers for Disease Control and Prevention (CDC)

---

The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

---